✨ Free AI Report
Marksans Pharma Limited: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Marksans Pharma Limited
Company Research

Marksans Pharma Limited: Business Overview, Financials & Competitive Analysis

Marksans Pharma Limited scores 7/10 on the AskCyborg Cyborg Score (Strong). Growing mid-cap pharma company with strong OTC portfolio, expanding international presence, and solid margin profile targeting multi-year growth acceleration. Q3 FY26 revenue grew 10.6% YoY to ₹754.4 crore with EBITDA of ₹160.7 crore. 9M FY26 EBITDA margin of 19.4% aligns with full-year guidance of 19-20%. Recent regulatory approvals and.

What is Marksans Pharma Limited's industry? Marksans Pharma Limited (marksanspharma.com) operates in Pharmaceutical Formulations - Generic & OTC. AskCyborg classifies Marksans Pharma Limited under Pharmaceutical Formulations - Generic & OTC in its company registry.

Marksans Pharma is an India-based company engaged in research, manufacturing and marketing of generic pharmaceutical formulations in global markets. The company's portfolio comprises OTC products (74% of FY24 revenue)...

7/ 10Strong

Cyborg Score thesis

Growing mid-cap pharma company with strong OTC portfolio, expanding international presence, and solid margin profile targeting...

Read the full analyst-debate transcript →
Industry Pharmaceutical Formulations - Generic & OTC
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Marksans Pharma Limited Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Marksans Pharma Limited

AskCyborg analysts argue the bull and bear cases for Marksans Pharma Limited across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Marksans Pharma Limited OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Marksans Pharma Limited Overview

Pro stress-test →

Marksans Pharma is an India-based company engaged in research, manufacturing and marketing of generic pharmaceutical formulations in global markets. The company's portfolio comprises OTC products (74% of FY24 revenue) including pain management, cough and cold, and digestive remedies, plus prescription products (26%) covering cardiovascular, CNS, and anti-diabetic drugs.

Strategic Profile

Pro stress-test →

The company's manufacturing capacity has reached 26 billion units per year, a fourfold increase over several years. Marksans aims for ₹4,000 crore revenue in 2-3 years with projected 20% growth in the US market. The company has recently formed wholly owned subsidiaries in Ireland and Canada to expand its pharmaceutical business internationally.

Competitive Landscape

Pro stress-test →

Marksans Pharma's peers include Sun Pharmaceutical Industries Ltd, Divis Laboratories Ltd, Torrent Pharmaceuticals Ltd, Cipla Ltd, Dr Reddys Laboratories Ltd, Zydus Lifesciences Ltd, and Mankind Pharma Ltd. Marksans differentiates through strong OTC presence and expanding manufacturing scale across regulated markets.

Industry Context

Marksans Pharma Limited operates in Pharmaceutical Formulations - Generic & OTC.

Key facts

Founded: 1992 · Headquarters: Mumbai, India · Revenue: ₹2,094.8Cr (9M FY26) · Market cap: $0.95B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Marksans Pharma Limited.

  • Q3 net profit rose to ₹1.13B from ₹1.05B YoY, demonstrating profitability growth.
  • Stock surged 9.5% on February 3, 2026, reflecting positive market sentiment.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Formed wholly owned subsidiaries Marksans Pharma Europe Limited and Marksans Canada Inc.
  • February 2026Q3 FY26 results showed 10.6% YoY revenue growth with EBITDA margin aligned to guidance
  • +2 moreTrack every material event for Marksans Pharma Limited as it happens. Explore monitoring →
Get alerted when Marksans Pharma Limited has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Generic PharmaceuticalsLeading large-cap Indian pharma manufacturer→Generic PharmaceuticalsMajor competitor with diverse therapeutic portfolio→Generic PharmaceuticalsAPI and formulation manufacturer→Generic PharmaceuticalsGlobal pharmaceutical company→

Compare Marksans Pharma Limited with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Marksans Pharma Limited operates in Pharmaceutical Formulations - Generic & OTC. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Formulations - Generic & OTC research →
NEW · MCP server

Ask your AI assistant about Marksans Pharma Limited

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Marksans Pharma Limited and its top competitor on Cyborg Score”
“What did Marksans Pharma Limited do this quarter?”
“Is Marksans Pharma Limited a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Marksans Pharma Limited do?+
Marksans Pharma is an India-based company engaged in research, manufacturing and marketing of generic pharmaceutical formulations in global markets. The company's portfolio comprises OTC products (74% of FY24 revenue)...
What is Marksans Pharma Limited's Cyborg Score?+
Marksans Pharma Limited has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Marksans Pharma Limited's main competitors?+
Named competitors include Generic Pharmaceuticals, Generic Pharmaceuticals, Generic Pharmaceuticals, Generic Pharmaceuticals. The full competitive landscape is in the AskCyborg report.
How can I get the full Marksans Pharma Limited research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Marksans Pharma Limited research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Marksans Pharma Limited over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceutical Formulations - Generic & OTC research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Marksans Pharma Limited